Business Context and Reporting Period
Company: MiMedx Group, Inc.
Filing Type: Form 8-K (Current Report)
Date of Report: September 20, 2018
Event: Regulation FD Disclosure regarding Nasdaq listing status.
Key Financial Metrics
This filing does not contain financial performance data. The filing text does not provide a clear value for revenue, profit, cash flow, margins, debt, or liquidity.
Material Changes
The primary material event is the Nasdaq Hearings Panel granting MiMedx an extension to regain compliance with SEC reporting obligations and Nasdaq listing rules. The extension is valid through February 25, 2019.
Guidance, Outlook, and Risks
- Condition for Continued Listing: The Company must regain compliance with SEC reporting obligations and Nasdaq listing rules by February 25, 2019.
- Reporting Requirement: The Company must provide the Panel with certain interim progress reports.
- Consequence of Non-Compliance: If the Company fails to regain compliance by the deadline or if the Panel reconsiders the extension based on interim reports, Nasdaq will suspend trading in the Company's common stock.
- Forward-Looking Statements: Management cautions that actual results may differ materially from expectations due to uncertainties regarding the ability to cure delinquencies in compliance.
Investor Verification Checklist
- Verify the Company's current status regarding SEC reporting delinquencies.
- Monitor interim progress reports submitted to the Nasdaq Hearings Panel.
- Confirm whether the Company regains full compliance with Nasdaq listing rules before February 25, 2019.
- Review the full text of the press release furnished as Exhibit 99.1 for additional details.